Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human EGFR2 (HER2) is observed frequent in pancreatic adenocarcinomas. Because of co-activation of these two signaling pathways, we assessed the efficacy o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press Inc. 2013
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579317/
https://ncbi.nlm.nih.gov/pubmed/23441129
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares